Literature DB >> 22460880

Drug development: Raise standards for preclinical cancer research.

C Glenn Begley1, Lee M Ellis.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22460880     DOI： 10.1038/483531a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Raising the bar for cancer therapy models.

Authors:  Giulio Francia; Robert S Kerbel
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

2.  High drug attrition rates--where are we going wrong?

Authors:  Lisa Hutchinson; Rebecca Kirk
Journal:  Nat Rev Clin Oncol       Date:  2011-03-30       Impact factor: 66.675

3.  Believe it or not: how much can we rely on published data on potential drug targets?

Authors:  Florian Prinz; Thomas Schlange; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

Review 4.  Drug development and clinical trials--the path to an approved cancer drug.

Authors:  Eric H Rubin; D Gary Gilliland
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

5.  Do pressures to publish increase scientists' bias? An empirical support from US States Data.

Authors:  Daniele Fanelli
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240
  5 in total
  814 in total

1.  Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis.

Authors:  Michael T Marrone; Corinne E Joshu; Sarah B Peskoe; Angelo M De Marzo; Christopher M Heaphy; Shawn E Lupold; Alan K Meeker; Elizabeth A Platz
Journal:  Clin Chem       Date:  2018-12-05       Impact factor: 8.327

2.  ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling.

Authors:  Jiyang Yu; Jose Silva; Andrea Califano
Journal:  Bioinformatics       Date:  2015-09-28       Impact factor: 6.937

3.  Genes, Environments, and Sex Differences in Alcohol Research.

Authors:  Jessica E Salvatore; Seung Bin Cho; Danielle M Dick
Journal:  J Stud Alcohol Drugs       Date:  2017-07       Impact factor: 2.582

4.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

5.  Epitope mapping of commercial antibodies that detect myocilin.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Michael P Fautsch; Raquel L Lieberman
Journal:  Exp Eye Res       Date:  2018-05-09       Impact factor: 3.467

6.  The Tangled Knots of Neuroscientific Experimentation.

Authors:  Stefan Frisch
Journal:  Integr Psychol Behav Sci       Date:  2021-07-22

7.  From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry.

Authors:  Russell P Grant; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2014-05-08       Impact factor: 8.327

8.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

9.  Assessing the validity and reproducibility of genome-scale predictions.

Authors:  Lauren A Sugden; Michael R Tackett; Yiannis A Savva; William A Thompson; Charles E Lawrence
Journal:  Bioinformatics       Date:  2013-09-17       Impact factor: 6.937

10.  Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Authors:  Anahit Ghochikyan; Arpine Davtyan; Armine Hovakimyan; Hayk Davtyan; Anna Poghosyan; Alexander Bagaev; Ravshan I Ataullakhanov; Edward L Nelson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2013-10-06       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.